Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells

Cancer Gene Therapy volume 17, pages 541–549 (2010)Cite this article

Subjects

Abstract

Adenovirus-mediated gene therapy shows remarkable promise as a new strategy for advanced pancreatic cancer, but satisfactory clinical results have not yet been obtained. To improve this gene therapy, we investigated the effects of gemcitabine (GEM) on transgene expression by adenoviral vectors and their biological effects. We used Ad-lacZ and adenoviral vector-expressing NK4 (Ad-NK4) as representative adenoviral vectors. These vectors express β-galactosidase (β-gal) and NK4 (which inhibits the invasion of cancer cells), respectively, under the control of the CMV promoter. Cells were infected with the individual adenoviruses and then treated with GEM. GEM increased β-gal mRNA expression and β-gal activity, and increased NK4 expression in both culture media and within infected cells, in dose-dependent manners. The increased expression of NK4 delivered by Ad-NK4 had biological effects by inhibiting the invasion of cancer cells. GEM also enhanced NK4 expression in SUIT-2 cells transfected with an NK4-expressing plasmid, suggesting that GEM enhanced CMV promoter activity. In in vivo experiments, NK4 expression within subcutaneously implanted tumors was increased in GEM-treated mice compared with control mice. These results suggest that adenovirus-mediated gene therapy with GEM may be a promising approach for treating pancreatic cancer, and that this combination therapy may decrease the risks of side effects.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Ghaneh P, Costello E, Neoptolemos JP . Biology and management of pancreatic cancer. Gut 2007; 56: 1134–1152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Hagihara A et al. Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 2008; 38: 755–761.

    Article  PubMed  Google Scholar 

  3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ . Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.

    Article  PubMed  Google Scholar 

  4. Sener SF, Fremgen A, Menck HR, Winchester DP . Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the national cancer database. J Am Coll Surg 1999; 189: 1–7.

    Article  CAS  PubMed  Google Scholar 

  5. Mancuso A, Calabro F, Sternberg CN . Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 2006; 58: 231–241.

    Article  PubMed  Google Scholar 

  6. Kang SP, Saif MW . Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP 2008; 9: 251–266.

    PubMed  Google Scholar 

  7. Bhattacharyya M, Lemoine NR . Gene therapy developments for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20: 285–298.

    Article  CAS  PubMed  Google Scholar 

  8. St George JA . Gene therapy progress and prospects: adenoviral vectors. Gene Ther 2003; 10: 1135–1141.

    Article  CAS  PubMed  Google Scholar 

  9. Crystal RG . Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270: 404–410.

    Article  CAS  PubMed  Google Scholar 

  10. Maehara N, Nagai E, Mizumoto K, Sato N, Matsumoto K, Nakamura T et al. Gene transduction of NK4, HGF antagonist, inhibits in vitro invasion and in vivo growth of human pancreatic cancer. Clin Exp Metastasis 2002; 19: 417–426.

    Article  CAS  PubMed  Google Scholar 

  11. Ogura Y, Mizumoto K, Nagai E, Murakami M, Inadome N, Saimura M et al. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Ther 2006; 13: 520–529.

    Article  CAS  PubMed  Google Scholar 

  12. Egami T, Ohuchida K, Mizumoto K, Onimaru M, Toma H, Nishio S et al. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake. Clin Cancer Res 2008; 14: 1859–1867.

    Article  CAS  PubMed  Google Scholar 

  13. Svensson RU, Barnes JM, Rokhlin OW, Cohen MB, Henry MD . Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res 2007; 67: 10445–10454.

    Article  CAS  PubMed  Google Scholar 

  14. Kim KI, Kang JH, Chung JK, Lee YJ, Jeong JM, Lee DS et al. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med 2007; 48: 1553–1561.

    Article  CAS  PubMed  Google Scholar 

  15. Vereecque R, Saudemont A, Wickham TJ, Gonzalez R, Hetuin D, Fenaux P et al. Gamma-irradiation enhances transgene expression in leukemic cells. Gene Ther 2003; 10: 227–233.

    Article  CAS  PubMed  Google Scholar 

  16. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T . HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997; 420: 1–6.

    Article  CAS  PubMed  Google Scholar 

  17. Maemondo M, Narumi K, Saijo Y, Usui K, Tahara M, Tazawa R et al. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. Mol Ther 2002; 5: 177–185.

    Article  CAS  PubMed  Google Scholar 

  18. Korst RJ, Bewig B, Crystal RG . In vitro and in vivo transfer and expression of human surfactant SP-A- and SP-B-associated protein cDNAs mediated by replication-deficient, recombinant adenoviral vectors. Hum Gene Ther 1995; 6: 277–287.

    Article  CAS  PubMed  Google Scholar 

  19. Ohuchida K, Mizumoto K, Ogura Y, Ishikawa N, Nagai E, Yamaguchi K et al. Quantitative assessment of telomerase activity and human telomerase reverse transcriptase messenger RNA levels in pancreatic juice samples for the diagnosis of pancreatic cancer. Clin Cancer Res 2005; 11: 2285–2292.

    Article  CAS  PubMed  Google Scholar 

  20. Zhang L, Mizumoto K, Sato N, Ogawa T, Kusumoto M, Niiyama H et al. Quantitative determination of apoptotic death in cultured human pancreatic cancer cells by propidium iodide and digitonin. Cancer Lett 1999; 142: 129–137.

    Article  CAS  PubMed  Google Scholar 

  21. Sato N, Maehara N, Mizumoto K, Nagai E, Yasoshima T, Hirata K et al. Telomerase activity of cultured human pancreatic carcinoma cell lines correlates with their potential for migration and invasion. Cancer 2001; 91: 496–504.

    Article  CAS  PubMed  Google Scholar 

  22. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T . Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998; 17: 3045–3054.

    Article  CAS  PubMed  Google Scholar 

  23. Das KC, White CW . Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997; 272: 14914–14920.

    Article  CAS  PubMed  Google Scholar 

  24. Bruening W, Giasson B, Mushynski W, Durham HD . Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. Nucleic Acids Res 1998; 26: 486–489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Lee Y, Sohn WJ, Kim DS, Kwon HJ . NF-kappaB- and c-Jun-dependent regulation of human cytomegalovirus immediate-early gene enhancer/promoter in response to lipopolysaccharide and bacterial CpG-oligodeoxynucleotides in macrophage cell line RAW 264.7. Eur J Biochem 2004; 271: 1094–1105.

    Article  CAS  PubMed  Google Scholar 

  26. Benedict CA, Angulo A, Patterson G, Ha S, Huang H, Messerle M et al. Neutrality of the canonical NF-kappaB-dependent pathway for human and murine cytomegalovirus transcription and replication in vitro. J Virol 2004; 78: 741–750.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Sambucetti LC, Cherrington JM, Wilkinson GW, Mocarski ES . NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J 1989; 8: 4251–4258.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Alemany R, Balague C, Curiel DT . Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723–727.

    Article  CAS  PubMed  Google Scholar 

  29. Jain RK . Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 1989; 81: 570–576.

    Article  CAS  PubMed  Google Scholar 

  30. Yuan F . Transvascular drug delivery in solid tumors. Semin Radiat Oncol 1998; 8: 164–175.

    Article  CAS  PubMed  Google Scholar 

  31. Nagano S, Perentes JY, Jain RK, Boucher Y . Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res 2008; 68: 3795–3802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Yun CO . Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr Opin Mol Ther 2008; 10: 356–361.

    PubMed  Google Scholar 

  33. Yao X, Yoshioka Y, Eto Y, Morishige T, Okada Y, Mizuguchi H et al. TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection. Biochem Biophys Res Commun 2007; 362: 419–424.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Mrs Shoko Sadatomi for her outstanding technical support. This study was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Author information

Authors and Affiliations

  1. Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Maidashi, Fukuoka, Japan

    M Onimaru, K Ohuchida, T Egami, K Mizumoto, E Nagai, L Cui, H Toma & M Tanaka

  2. Department of Advanced Medical Initiatives, Graduate School of Medical Sciences, Kyushu University, Maidashi, Fukuoka, Japan

    M Onimaru, K Ohuchida & M Hashizume

  3. Kyushu University Hospital Cancer Center, Maidashi, Fukuoka, Japan

    K Mizumoto

  4. Department of Tumor Dy,

    K Matsumoto

  5. namics and Regulation, Cancer Research Institute, Kanazawa University, Kanazawa, Japan

    K Matsumoto

Authors
  1. M Onimaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Ohuchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Egami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Mizumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H Toma
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Hashizume
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to K Ohuchida or K Mizumoto.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Onimaru, M., Ohuchida, K., Egami, T. et al. Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells. Cancer Gene Ther 17, 541–549 (2010). https://doi.org/10.1038/cgt.2010.9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2010.9

Keywords

Search

Advanced search

Quick links